Virus-like particles (VLPs) have been shown to be strong activators of dendritic cells (DCs).
DCs are the most potent antigen presenting cells (APCs) and their activation prompts the …

Human papillomavirus (HPV) infection of the genital tract is common in young sexually
active individuals, the majority of whom clear the infection without overt clinical disease …

Abstract Adjuvant System 04 (AS04) combines the TLR4 agonist MPL (3-O-desacyl-4′-
monophosphoryl lipid A) and aluminum salt. It is a new generation TLR-based adjuvant …

This ninetieth volume of the IARC Monographs on the Evaluation of Carcinogenic Risks to
Humansconsiders human papillomaviruses (HPVs) which were evaluated by a previous …

Genital human papillomavirus (HPV) infection with both low-and high-risk types is common,
but most infections resolve as a result of a cell-mediated immune response. Failure to …

Human papillomavirus virus-like particles (HPV VLP) can be generated by the synthesis and
self-assembly in vitro of the major virus capsid protein L1. HPV L1 VLPs are morphologically …

Virus‐like particles (VLPs) mimic the whole construct of virus particles devoid of viral
genome as used in subunit vaccine design. VLPs can elicit efficient protective immunity as …

Problem Women with antiphospholipid antibodies (aPL) are at risk for recurrent miscarriage,
pre‐eclampsia, and pre‐term labor. aPL target the placenta directly by binding to beta2 …

HPV infection in the genital tract is common in young sexually active individuals, the majority
of whom clear the infection without overt clinical disease. However most of those who …

A single dose of human papillomavirus (HPV) vaccine against HPV infection (prerequisite
for cervical cancer) appears to be as efficacious as two or three doses, despite inducing …